Cytoplasmic EpCAM over-expression is associated with favorable clinical outcomes in pancreatic cancer patients with hepatitis B virus negative infection

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 12, 2015, Pages 22204-22216

  Meng, Yao ^a   Xu, Bao Qing ^a   Fu, Zhi Guang ^a   Wu, Bo ^a   Xu, Bo ^b   Chen, Zhi Nan ^a   Li, Ling ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cytoplasmic EpCAM; HBV; Pancreatic cancer; Prognosis; Survival

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHRONIC PANCREATITIS; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; TISSUE MICROARRAY; WESTERN BLOTTING;

EID: 84957109579     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Ryan DP, Hong TS and Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371: 1039-1049.
3. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C and Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
4. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J and Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703.
5. Dolle L, Theise ND, Schmelzer E, Boulter L, Gires O and van Grunsven LA. EpCAM and the biology of hepatic stem/progenitor cells. Am J Physiol Gastrointest Liver Physiol 2015; 308: G233-250.
6. Schnell U, Cirulli V and Giepmans BN. EpCAM: structure and function in health and disease. Biochim Biophys Acta 2013; 1828: 1989-2001.
7. Patriarca C, Macchi RM, Marschner AK and Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 2012; 38: 68-75.
8. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM and Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 2010; 31: 1913-1921.
9. Imrich S, Hachmeister M and Gires O. EpCAM and its potential role in tumor-initiating cells. Cell Adh Migr 2012; 6: 30-38.
10. Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, Mizukoshi E, Ikeda H, Zen Y, Takamura H, Wang XW and Kaneko S. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology 2013; 57: 1484-1497.
11. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
12. Fong D, Steurer M, Obrist P, Barbieri V, Margreiter R, Amberger A, Laimer K, Gastl G, Tzankov A and Spizzo G. Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol 2008; 61: 31-35.
13. Akita H, Nagano H, Takeda Y, Eguchi H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Takahashi H, Ohigashi H, Tomita Y, Ishikawa O, Mori M and Doki Y. Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity. Oncogene 2011; 30: 3468-3476.
14. Gosens MJ, van Kempen LC, van de Velde CJ, van Krieken JH and Nagtegaal ID. Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol 2007; 20: 221-232.
15. Alberti S, Ambrogi F, Boracchi P, Fornili M, Querzoli P, Pedriali M, La Sorda R, Lattanzio R, Tripaldi R, Piantelli M, Biganzoli E and Coradini D. Cytoplasmic Trop-1/Ep-CAM overexpression is associated with a favorable outcome in node-positive breast cancer. Jpn J Clin Oncol 2012; 42: 1128-1137.
16. Qin J, Yang B, Xu BQ, Smithc A, Xu L, Yuan JL and Li L. Concurrent CD44s and STAT3 expression in human clear cell renal cellular carcinoma and its impact on survival. Int J Clin Exp Pathol 2014; 7: 3235-3244.
17. Li L, Tang W, Wu X, Karnak D, Meng X, Thompson R, Hao X, Li Y, Qiao XT, Lin J, Fuchs J, Simeone DM, Chen ZN, Lawrence TS and Xu L. HAb18G/CD147 promotes pSTAT3-mediated pancreatic cancer development via CD44s. Clin Cancer Res 2013; 19: 6703-6715.
18. Li L, Hao X, Qin J, Tang W, He F, Smith A, Zhang M, Simeone DM, Qiao XT, Chen ZN, Lawrence TS and Xu L. Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice. Gastroenterology 2014; 146: 1108-1118.
19. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A, Mattern J, Li Z, Kolb A, Moldenhauer G, Altevogt P, Wirth T, Werner J, Schemmer P, Buchler MW, Salnikov AV and Herr I. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 2009; 58: 949-963.
20. Tsaktanis T, Kremling H, Pavsic M, von Stackelberg R, Mack B, Fukumori A, Steiner H, Vielmuth F, Spindler V, Huang Z, Jakubowski J, Stoecklein NH, Luxenburger E, Lauber K, Lenarcic B and Gires O. Cleavage and Cell Adhesion Properties of Human Epithelial Cell Adhesion Molecule (HEPCAM). J Biol Chem 2015; 290: 24574-24591.
21. Winkler J, Martin-Killias P, Pluckthun A and Zangemeister-Wittke U. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol Cancer Ther 2009; 8: 2674-2683.
22. Cole SL and Vassar R. The Alzheimer’s disease beta-secretase enzyme, BACE1. Mol Neurodegener 2007; 2: 22.
23. Driemel C, Kremling H, Schumacher S, Will D, Wolters J, Lindenlauf N, Mack B, Baldus SA, Hoya V, Pietsch JM, Panagiotidou P, Raba K, Vay C, Vallbohmer D, Harreus U, Knoefel WT, Stoecklein NH and Gires O. Context-dependent adaption of EpCAM expression in early systemic esophageal cancer. Oncogene 2014; 33: 4904-4915.
24. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M and Gires O. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11: 162-171.
25. Fong D, Moser P, Kasal A, Seeber A, Gastl G, Martowicz A, Wurm M, Mian C, Obrist P, Mazzoleni G and Spizzo G. Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer. Histopathology 2014; 64: 683-692.
26. Fong D, Seeber A, Terracciano L, Kasal A, Mazzoleni G, Lehne F, Gastl G and Spizzo G. Expression of EpCAM (MF) and EpCAM (MT) variants in human carcinomas. J Clin Pathol 2014; 67: 408-414.
27. Gires O and Stoecklein NH. Dynamic EpCAM expression on circulating and disseminating tumor cells: causes and consequences. Cell Mol Life Sci 2014; 71: 4393-4402.
28. Song E, Chen J, Ou Q and Su F. Rare occurrence of metastatic colorectal cancers in livers with replicative hepatitis B infection. Am J Surg 2001; 181: 529-533.
29. Wei XL, Qiu MZ, Chen WW, Jin Y, Ren C, Wang F, Luo HY, Wang ZQ, Zhang DS, Wang FH, Li YH and Xu RH. The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. J Transl Med 2013; 11: 249.
30. Andersen ES, Omland LH, Jepsen P, Krarup H, Christensen PB, Obel N and Weis N. Risk of alltype cancer, hepatocellular carcinoma, non-Hodgkin lymphoma and pancreatic cancer in patients infected with hepatitis B virus. J Viral Hepat 2015; 22: 828-834.
31. Dumitrascu T, Pineau P, Dima S, Stroescu C, Brasoveanu V, Herlea V, Ionescu M and Popescu I. Impact of Hepatitis B Virus on Clinicopathological Features and Outcomes After Resection for Pancreatic Adenocarcinoma. Anticancer Res 2015; 35: 5123-5128.
32. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, Lu SN and Chen CJ. Risk of pancreatic cancer in chronic hepatitis B virus infection: data from the REVEAL-HBV cohort study. Liver Int 2010; 30: 423-429.
33. Fan H, Zhang H, Pascuzzi PE and Andrisani O. Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2. Oncogene 2015; [Epub ahead of print].
34. Kimura O, Kondo Y, Kogure T, Kakazu E, Ninomiya M, Iwata T, Morosawa T and Shimosegawa T. Expression of EpCAM increases in the hepatitis B related and the treatmentresistant hepatocellular carcinoma. Biomed Res Int 2014; 2014: 172913.
35. Arzumanyan A, Friedman T, Ng IO, Clayton MM, Lian Z and Feitelson MA. Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res 2011; 71: 3701-3708.